CRT-800.02 Eligibility for PCSK9 Treatment in 734 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With Heterozygous Familial Hypercholesterolemia With LDL Cholesterol >100 Mg/dl and/or Atherosclerotic Cardiovascular Disease With LDL Cholesterol >70 Mg/dl Despite Maximal Tolerated Cholesterol Lowering Therapy

Marloe Prince,Charles J. Glueck,Parth Shah,Kevin Lee,Vybhav Jetty,Ping Wang

CRT-800.02 Eligibility for PCSK9 Treatment in 734 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With Heterozygous Familial Hypercholesterolemia With LDL Cholesterol >100 Mg/dl and/or Atherosclerotic Cardiovascular Disease With LDL Cholesterol >70 Mg/dl Despite Maximal Tolerated Cholesterol Lowering Therapy

2016

Marloe Prince
Charles J. Glueck
Parth Shah
Kevin Lee
Vybhav Jetty
Ping Wang

Lowering of LDL cholesterol (LDLC) has been revolutionized by the recent release of the PCSK9 inhibitors, Alirocumab (Praluent) and Evolocumab (Repatha). PCSK9 inhibitors have approved indications as an adjunct to diet and maximally tolerated statin therapy for patients with heterozygous familial

Keywords:

Evolocumab
Cardiology
Gastroenterology
Statin
Atherosclerotic cardiovascular disease
PCSK9
Familial hypercholesterolemia
Alirocumab
Cholesterol
Diabetes mellitus
Endocrinology
Internal medicine
Medicine
treatment center
ldl cholesterol

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations